• Vir Biotechnology named David Liu executive vice president, chief medical officer, effective Oct. 12, 2026.
• Liu will lead clinical development, medical affairs, regulatory affairs as Vir advances its Phase 3 chronic hepatitis delta program.
• He joins from Nuvation Bio, where he served as CMO and built its global clinical R&D organization.
• Liu previously served as CMO of 3D Medicines.
• Earlier roles include executive medical director at Celgene, leadership posts at Bristol Myers Squibb, scientist at AstraZeneca.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070830BIZWIRE_USPR_____20261007_BW701943) on October 07, 2026, and is solely responsible for the information contained therein.